FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab clinical trials

I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

This study, called I5T-MC-AACI, is looking at a new medicine called Donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe, how well people tolerate it, and if it helps with symptoms. It's a Phase II study, which means it's still in early testing.